Lexicon Pharma (LXRX) Reports In-Line Q3 EPS
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.05 +0.49%
Revenue Growth %: -78.9%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -78.9%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $160 thousand versus the consensus estimate of $2.06 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike
- Redburn upgrades Southwest, stays bullish on Delta and United
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
